Versuchen GOLD - Frei
Coliform bacteria and E. coli in pharma water systems: A hidden threat to product integrity
Express Pharma
|May 2025
Water quality is critical in pharma manufacturing, and contamination by coliforms or E. coli can threaten product safety and compliance. Dr Girish B Mahajan, Sr VP - Microbiology, HiMedia Laboratories examines the risks, regulatory focus, and new technologies for real-time microbial monitoring in this article
-

The COVID-19 pandemic brought microbiology to the public eye, making terms like RT-PCR, antigen, and PPE kit part of everyday discussions. In the pharmaceutical world, another set of terms-coliforms and E. coli-carry immense importance, especially where water quality is concerned. Water is a critical utility in pharma manufacturing processes and is used in various stages including formulation, cleaning, and even as raw material in some products. Any microbial contamination in the water supply chain can have cascading effects on product integrity, batch sterility, and ultimately patient safety.
Pharma-grade water systems like Purified Water (PW), Water for Injection (WFI), and Clean-in-Place (CIP) are designed with rigorous microbial quality parameters. However, coliform bacteria-especially E. coli-serve as early indicators of water system failures and contamination by fecal matter or biofilm development. A recent E. coli outbreak in 2024 due to contaminated food illustrated how lapses in microbial control can spiral into public health emergencies. For the pharma industry, the implications are even more severe, with potential regulatory actions, product recalls, and brand damage.
Understanding coliforms and their relevance in pharma
Coliform bacteria, comprising genera such as Escherichia, Citrobacter, Enterobacter, and Klebsiella, are Gram-negative, rod-shaped microorganisms commonly found in the environment, including soil, surface water, and the gastrointestinal tracts of warm-blooded animals. Though most are not pathogenic, their presence in pharma water systems-especially Escherichia coli, which indicates faecal origin-raises serious red flags regarding the integrity of production processes.
Diese Geschichte stammt aus der May 2025-Ausgabe von Express Pharma.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Express Pharma

Express Pharma
Flexotherm Heating Tapes & Cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
October 2025

Express Pharma
DRIVING INDIA'S INNOVATION EDGE
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership
16 mins
October 2025

Express Pharma
Al compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations
7 mins
October 2025

Express Pharma
PRIME NEO: New age doors from Gandhi Automation
Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.
1 mins
October 2025

Express Pharma
Unani Medicine: At crossroads of tradition and modernity
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
7 mins
October 2025

Express Pharma
Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand
The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.
1 min
October 2025

Express Pharma
Sustainable packaging with Romaco and Liveo Research
Recycable blister packs
3 mins
October 2025

Express Pharma
With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here
As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.
3 mins
October 2025

Express Pharma
Cell therapy's next chapter: Industry embraces in-vivo innovation
Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases
4 mins
October 2025

Express Pharma
Research misconduct ...can delay meaningful and reliable discoveries
Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions
6 mins
October 2025
Listen
Translate
Change font size